Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.
Valentin Goede
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche
Kirsten Fischer
Other Remuneration - Roche
Kathryn Humphrey
Employment or Leadership Position - Roche
Elina Asikanius
Employment or Leadership Position - Roche
Stock Ownership - Roche
Raymonde Busch
No relevant relationships to disclose
Anja Engelke
Other Remuneration - Roche
Clemens M. Wendtner
Consultant or Advisory Role - Roche
Honoraria - Roche
Olga Samoylova
No relevant relationships to disclose
Tatiana Chagorova
No relevant relationships to disclose
Marie-Sarah Dilhuydy
Honoraria - Roche
Javier De La Serna Torroba
Honoraria - Roche
Thomas Illmer
No relevant relationships to disclose
Stephen Opat
Consultant or Advisory Role - Roche
Carolyn Owen
No relevant relationships to disclose
Karl A Kreuzer
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Anton W Langerak
No relevant relationships to disclose
Matthias Ritgen
Research Funding - Roche
Stephan Stilgenbauer
Consultant or Advisory Role - Mundipharma; Roche
Honoraria - Mundipharma; Roche
Research Funding - Mundipharma; Roche
Michael Wenger
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Michael Hallek
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche